Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Viral infections and allergen exposure are 2 of the most common causes of acute wheezing and exacerbations of asthma in both children and adults. Clinical research findings indicate that there are synergistic interactions between allergy and viral infection that cause increased severity of asthma exacerbations. This article summarizes the current literature linking these 2 risk factors for asthma exacerbation, and reviews experimental data suggesting potential mechanisms for interactions between viral infection and allergy that cause asthma exacerbations. Finally, the authors discuss clinical evidence that treatment of allergic inflammation could help to reduce the frequency and severity of virus-induced exacerbations of asthma.

**ROLE OF VIRAL INFECTIONS IN WHEEZING ILLNESSES**

Overall, 25% to 30% of infants experience at least one episode of wheezing during their first year of life. This incidence increases to 40% of children by age 3 and almost half of all children by age 6 years.\(^1\) Two major pathogens, respiratory syncytial virus (RSV) and human rhinovirus (HRV), cause most of these illnesses. RSV is the major pathogen associated with wheezing illnesses in children younger than 2 years.\(^2\)–\(^4\) Of other viruses causing wheezing illnesses in infancy, HRV is next most common, and a variety of viruses (coronaviruses, metapneumoviruses, parainfluenza viruses, influenza viruses, bocavirus) also cause significant numbers of illnesses.

In children with established asthma, from 80% to 85% of asthma exacerbations are related to viral illness and up to two-thirds of those illnesses are caused by HRVs.\(^5\)
Asthma exacerbations in adults are also commonly caused by viral infections, usually HRV or influenza viruses. The etiology of virus-induced wheezing illnesses varies with the season: RSV, metapneumoviruses, and influenza viruses (with the notable exception of 2009 H1N1) are usually limited to the winter and early spring. HRV infections are most common in the spring and fall, but can occur throughout the year. Of note, asthma exacerbations are also quite seasonal, and seasonal peaks in children occur regularly in the fall and spring. In Canada, the peaks in pediatric asthma exacerbations occur approximately 17 days after Labor Day every year, and it is assumed that viral infections that are spread within schools are a major contributor to the fall peaks, and perhaps also in the spring after the children return from spring break.\(^6\)\(^7\) It is important to bear in mind that other environmental exposures, including allergens and pollutants, also vary by season, and it seems likely that a combination of environmental factors contributes to the seasonal peaks in exacerbation rates.

**ALLERGIC SENSITIZATION AS A RISK FACTOR FOR DEVELOPING VIRUS-INDUCED WHEEZE AND ASTHMA**

Sensitization to aeroallergens is a risk factor for the development of asthma, particularly when it occurs in the first few years of life.\(^8\) In addition, the prevalence of asthma is strongly related to serum IgE level.\(^8,9\) In a recent prospective cohort study, the risk for persistent wheeze was strongly linked to early sensitization and early infection.\(^8\) Mite-specific IgE titers of greater than 0.20 kU/L by age 2 years was associated with a 12.7% risk of persistent wheeze, increasing progressively to an 87.2% risk with increasing numbers of severe lower respiratory tract illnesses experienced.

In addition, in a longitudinal cohort, subjects with airway hyperresponsiveness (AHR) in early adulthood had higher IgE levels than subjects with past AHR or with lifelong normal responsiveness.\(^8,10\) Recent wheeze, AHR, and allergic sensitization all had a positive relation to serum IgE. The finding that young adults who are sensitized to common allergens are highly likely to have AHR even in the absence of symptoms is further evidence of the fundamental role of IgE-mediated responses in the natural history of AHR throughout childhood and into adulthood.

In a German birth cohort study, 90% of children with wheeze but no atopy lost their symptoms at school age and retained normal lung function at puberty.\(^11\) In contrast, sensitization to perennial allergens (eg, house dust mite, cat and dog hair) developing in the first 3 years of life was associated with a loss of lung function at school age. Allergen exposure also enhanced the development of airway hyperresponsiveness in sensitized children with wheeze. Of note, sensitization and exposure later in life had much weaker relationships to airway physiology, and sensitization to seasonal allergens was not an important influence.

An Australian birth cohort study involving babies with at least one parent with allergy or asthma provides strong evidence of an interaction between allergy and viral wheeze in early life. In this study, allergic sensitization before the age of 2 years was associated with viral-induced wheezing and asthma at age 5.\(^12\) Furthermore, there was a significant association between HRV- and RSV-induced wheezing and lower respiratory illness in the first year of life and the subsequent development of persistent wheeze at 5 years. These findings were found to be attributable only to those children who were sensitized to allergens in early life.

The Childhood Origins of Asthma (COAST) study is a high-risk birth cohort study in which families with at least one parent with allergies or asthma were enrolled preemptively, and both immune development and respiratory illnesses were prospectively evaluated.\(^13\) Children with aeroallergen sensitization and HRV-induced wheezing during
the first year of life had a high likelihood of developing asthma compared with patients with HRV wheezing within the first year of life without aeroallergen sensitization (86% vs 39%). At age 3 years, HRV wheezing status was the principal indicator of asthma risk, independent of sensitization status. Viral recovery at routine study visits was similar for children with and without asthma, suggesting that asthma is associated with greater severity of illness rather than an increased number of infections.

**ALLERGY AND VIRUS-INDUCED EXACERBATIONS OF ASTHMA**

There is strong clinical evidence that allergic sensitization and viral illnesses increase the risk of asthma exacerbation and hospitalization. In a cross-sectional study performed at a tertiary pediatric emergency department, allergy and viral infection (most commonly HRV) were both identified as risk factors for wheezing. Children who had HRV infection detected in combination with either eosinophilia or a positive radioallergosorbent test to common aeroallergens had the strongest odds of wheezing. A second study from the same group supported these findings, and also provided evidence that many children with isolated HRV infection do not wheeze in the absence of allergic cofactors. When considered together, these findings indicate that a large majority of emergent wheezing illnesses during childhood can be linked to infection with HRV, and that these wheezing attacks are most likely to occur in those who have HRV together with evidence of atopy or eosinophilic airway inflammation.

Other studies have gone one step further and have considered interactions between allergy, allergen exposure, and viral respiratory infection in causing wheezing illnesses. In a case-control study of 84 asthmatics admitted for acute exacerbations versus stable asthmatics and patients hospitalized for nonrespiratory diagnoses, a significantly higher proportion of children hospitalized for an acute exacerbation were virus-infected (44%) as compared with the stable asthmatics (18%) and nonrespiratory hospital admissions (17%; both P<.001). The combination of allergic sensitization and allergen exposure was also found more frequently in asthma hospitalization group (76%) than in the 2 control groups (48% and 28%, respectively, P<.001). In the multivariate analysis, the viral illness and allergic sensitization/exposure were no longer significant, but the combination of these risk factors dramatically increased the risk of hospital admission (odds ratio 19.4, P<.001), demonstrating the link between these factors in causing asthma exacerbations. Similar findings were reported in an earlier case-control study involving adults; the combination of sensitization, high exposure to one or more indoor allergens, and viral detection considerably increased the risk of being admitted to the hospital with asthma (odds ratio 8.4, 95% confidence interval 2.1–32.8; P = .002). Finally, in the Inner City Asthma Study (ICAS), children who were sensitized and highly exposed to cockroach allergen were more likely to be admitted to hospital, have more unscheduled medical visits, and more time off school than either nonexposed or nonsensitized children. Virology was not performed in ICAS, but it can be presumed that viral infections were important contributors to asthma morbidity in this population.

Many studies have assessed the impact of allergy and viral illness on asthma exacerbations in the community. In fact, most surveillance studies have focused on detection of HRV during periods of illness, but there are limited data available regarding true rates of infection in children with asthma. It is presumed that children frequently develop asymptomatic or mild infections that do not cause asthma exacerbations. If this is true, other factors must contribute to the risk of more severe illnesses and those with wheezing. To determine the contribution of viral infections and allergic sensitization to loss of asthma control, nasal secretions were obtained weekly in a group of 58 children with
asthma during peak HRV seasons (September and April).² As expected, virus-positive weeks were associated with greater severity of both cold and asthma symptoms. Clinically defined illnesses were then classified according to temporal association with detection of a respiratory virus. For virus-positive illnesses, the duration of cold and asthma symptoms was twice as long, and loss of asthma control occurred more frequently. Approximately two-thirds of the children were sensitized to common aeroallergens. When comparing sensitized with nonsensitized subjects, rates of infection were similar between the 2 groups; however, the sensitized group had 47% more virus-associated illnesses per season. Finally, nonsensitized subjects most commonly reported “none” or “mild” cold and asthma symptoms with their viral infections, whereas almost half of the viral infections in sensitized children resulted in moderate or severe cold or asthma symptoms (Fig. 1). These findings provide evidence that for children with asthma, atopy is an important risk factor for more severe cold and asthma symptoms.

RESPONSE TO EXPERIMENTAL HRV INFECTIONS IN ALLERGIC ASTHMATICS

Despite the initial assumption that HRV affects only the upper airway, studies using experimental inoculation followed by bronchoscopy or sputum induction have demonstrated HRV protein and mRNA in the lower airways.¹⁹–²¹ These studies indicate that HRV infections have the potential to modify and interact with allergic airway inflammation in the lower airways. Accordingly, subjects with allergic rhinitis who were inoculated with HRV had increased levels of histamine in bronchoalveolar lavage (BAL) samples immediately and 48 hours after antigen challenge during HRV infection.²² These same changes were not observed in nonallergic subjects infected with HRV and challenged to antigen, suggesting that the combination of viral infection and allergic disease leads to greater airway inflammation. In addition, experimentally induced HRV infection caused an enhanced eosinophilic response to allergen challenge in the allergic but not nonallergic subjects. This effect persisted for as long as 1 month after the acute HRV infection.

![Fig. 1. Effect of sensitization on the severity of cold and asthma symptoms associated with viral infection. Mod-Sev, moderate to severe.](image_url)

Kloepfer & Gern

556
Two additional studies determined whether the induction of allergic inflammation would increase the severity of HRV-induced respiratory symptoms. Contrary to expectations, allergen exposure before HRV inoculation led to either no change or a slight reduction in the severity and duration of cold symptoms.\textsuperscript{23,24} Of note is the difference in the sequence of administration of virus and allergen; this raises the question of which initiates the exacerbation, the virus or the allergic inflammation? Other factors to consider in thinking about the different outcomes of these studies are the nature of the allergen and pattern of exposure (dose and duration). It is possible that chronic low-dose allergen exposure before HRV infection amplifies the response to subsequent HRV inoculation.

Several studies have tested the theory that HRV infections cause distinct patterns of inflammation and changes in airway physiology in subjects with allergies or asthma. These studies have generally reported that the upper airway manifestations of HRV infections are similar in subjects with or without allergies or asthma, but that lower airway symptoms are increased in asthma. Two studies involving subjects with mild asthma have found similar cellular inflammation and proinflammatory cytokines in airway cells when compared with normal control subjects.\textsuperscript{25,26} In contrast, Message and colleagues\textsuperscript{27} found several asthma-related differences in the response to experimental HRV infection. In asthmatic subjects, HRV infection enhanced eosinophilic inflammation. In addition, virologic and clinical outcomes were related to deficient interferon (IFN)-\(\gamma\) and interleukin (IL)-10 responses and to augmented IL-4, IL-5, and IL-13 responses from blood and airway mononuclear cells. In a study of similar design, DeMore and colleagues\textsuperscript{25} found that numbers of airway eosinophils preinoculation were significantly related to cold scores induced by HRV infection. Collectively, these findings suggest that eosinophilic inflammation and T-helper 2 (Th2)-biased immune responses associated with allergic sensitization enhance the clinical severity of illness associated with HRV infection.

**MECHANISMS OF VIRUS-ALLERGEN INTERACTIONS**

There are several potential mechanisms for allergy and viral infections to synergize in causing wheezing, airway obstruction, and exacerbations of asthma (Box 1). These

| Potential interactions between allergy and viral infections |
|----------------------------------------------------------|
| **Common underlying predisposition**                     |
| • Interferon deficiency                                   |
| • Th2-biased immunity                                     |
| • Defect in anti-inflammatory responses                   |
| **Effects of allergen-induced inflammation**              |
| • Airway hyperresponsiveness                              |
| • Mucus production                                        |
| • Secondary depression of interferon synthesis            |
| **Epithelial abnormality**                                |
| • Reduced barrier function                                |
| • Abnormal repair mechanisms                              |
| • Airway remodeling                                       |
mechanisms, which are not mutually exclusive, include the possibility that there are common predisposing factors, interactions related to allergic inflammation, or deficiencies in the epithelium that predispose to allergy/asthma and increased severity of viral infections.

**Common Underlying Predisposition to Allergy and Viral Illnesses**

Likely risk factors that would predispose to both allergy/asthma and increased severity of viral infections include genetic or acquired abnormalities that lead to either underproduction of interferons or overproduction of Th2 cytokines, leading to a Th2 bias in the immune system. Clinical studies and experimental evidence from animal models suggest that either weak T-helper 1 (Th1) responses or Th2 bias can lead to more severe viral infections, and both of these abnormalities have also been implicated as a risk factor for allergies and asthma. In addition, children with recurrent respiratory infections were reported to have low IFN-α responses.

Interferons have also been related to outcomes of HRV illnesses in studies of volunteers inoculated with a safety-tested strain of HRV-16. Virus-induced IFN-γ responses in blood mononuclear cells were inversely associated with viral shedding after inoculation, and stronger Th1-like responses in sputum cells (higher IFN-γ/IL-5 mRNA ratio) during induced colds were associated with milder cold symptoms and more rapid clearance of the virus.

In addition to findings in the experimental inoculation model, there is evidence from clinical studies that asthma is associated with impaired virus-induced blood cell production of IFN-α and IFN-γ. Furthermore, some studies have reported that HRV-induced epithelial cell production of IFN-β and IFN-λ is also impaired in asthma, suggesting that interferon responses in asthma are generally depressed. On the other hand, these findings were not replicated in 2 recent studies examining cytokine responses in cultured airway epithelial cells, and so far studies of experimentally inoculated volunteers with asthma have not found evidence of increased HRV shedding in either the upper or lower airways. Additional studies of naturally acquired colds in patients with asthma are needed to resolve these differences.

Asthma is often associated with other inflammatory diseases such as atopic dermatitis and allergic rhinitis. Together with the propensity to develop more severe illnesses with respiratory infections, these findings suggest that T-regulatory cells or other anti-inflammatory mechanisms could be impaired in asthma. To date, studies of asthma and atopic dermatitis indicate that T-regulatory cell numbers may be increased in the blood and tissues, and this paradoxic finding could represent evidence of a compensatory response to inflammation. Important questions remain as to whether T-regulatory cell function or other anti-inflammatory regulatory mechanisms are impaired in asthma.

Finally, results obtained using animal models of respiratory viral infection suggest that biased innate immune responses to respiratory viruses in early life may establish overproduction of key cytokines such as IL-13, leading to suboptimal antiviral responses, increased risk for respiratory allergies, and changes in airway structure to promote asthma. These findings suggest that early innate immune responses to viral infection could promote the development of Th2 bias, leading to allergic diseases and asthma. This concept is further supported by a recent study of gene expression patterns from peripheral blood cells of children presenting for emergency treatment of acute asthma exacerbations, mostly associated with viral respiratory infections. Monocyte-dendritic cell populations had an up-regulated expression of FcεRIα with a concomitant gene expression signature that is representative of the IL-4/IL-13-dependent "alternatively activated" phenotype. Together, these studies
suggest an important link between early innate antiviral responses and the subsequent development of atopic diseases. This concept is also supported by evidence that asthma and allergy are associated with reductions in some innate antiviral responses, such as IFN-α secretion in response to Toll-like receptor (TLR)-7 and TLR-9.\textsuperscript{48,49}

**Effects of Allergen-Induced Inflammation on Antiviral Immunity**

It is well established that Th1- and Th2-like responses are counterregulated, and there is recent evidence to suggest that allergic inflammation can inhibit innate immune IFN responses under some conditions. For example, engagement of IgE receptors on plasmacytoid dendritic cells leads to reduced IFN-α production in response to either TLR-9 stimulation or incubation with influenza virus.\textsuperscript{50,51} This counterregulation between IgE-mediated and antiviral responses suggests a mechanism linking allergy, allergen exposure, and more severe viral illnesses.

There have been recent advances in understanding how environmental influences can modify dendritic cell and, subsequently, T-cell polarization through effects on the epithelium. Thymic stromal lymphopoietin (TSLP) is an epithelially derived cytokine that is induced by both viral infections and allergic inflammation. Cytokines such as IL-4 that are overproduced in asthma synergistically enhance TSLP secretion,\textsuperscript{52} which in turn acts on dendritic cells to promote the differentiation of naïve T cells into Th2 cells. This mechanism also provides a potential mechanism for synergy between viral respiratory infections and allergic airway inflammation.

**Defective Epithelial Barrier and Virus-Allergen Interactions**

Viral infections damage the barrier function of the airway epithelium, and one of the consequences of this effect may be to enhance absorption of allergens and/or irritants across the airway wall, leading to an increased inflammatory response.\textsuperscript{53} Furthermore, healthy, intact epithelial layers are difficult to infect with HRV in vitro. Viral replication is enhanced by mechanical or chemical damage to the epithelium, including removal of the apical layer of cultured epithelial cells.\textsuperscript{54,55} These findings suggest that eosinophilic inflammation and pollutants that damage the barrier function of airway epithelium could increase susceptibility to infection and/or lead to more severe infections. This effect could be compounded in asthma because of the association between asthma and defective epithelial repair processes.\textsuperscript{56} Finally, asthma is associated with remodeling of the airways, which includes increase in the numbers of mucus-secreting goblet cells. Experiments using epithelial cells differentiated at an air-liquid interface indicate that HRV replication is enhanced in goblet cells.\textsuperscript{57}

**DOES TREATMENT OF ALLERGIC ASTHMA DECREASE EXACERBATIONS?**

Given that viral infections contribute to most exacerbations of asthma, it seems likely that effective treatment against exacerbations of asthma might also reduce the number of virus-induced exacerbations of asthma. Surprisingly, there is little or no information about the effects of asthma controllers or relievers on defined virus-induced exacerbations.

Eosinophils tend to increase during the convalescence phase following an acute upper respiratory infection in patients with allergic airway disease, and presence of eosinophils in the airways has been identified as a risk factor for more severe colds.\textsuperscript{15,25} Furthermore, experimental HRV infection can enhance antigen-induced eosinophil influx in BAL and persistent eosinophil infiltration in bronchial mucosa and submucosa.\textsuperscript{22,58} These findings suggest that medications that reduce eosinophil recruitment or activation might be of clinical benefit in reducing the risk of exacerbations.
Both inhaled corticosteroids and montelukast can inhibit eosinophilic airway inflammation, and reduce the risk of exacerbations (inhaled corticosteroids more so than montelukast). To date there is only indirect evidence that these treatments can specifically prevent virus-induced exacerbations. A recent study showed a significant decrease in eosinophil-derived neurotoxin (EDN) levels in patients started on montelukast after an RSV infection. Furthermore, montelukast-induced reductions in EDN levels were associated with a significant decrease in wheezing episodes in follow-up. Finally, omalizumab reduces the risk of exacerbations in patients with allergic asthma, and provides an ideal tool to determine whether inhibiting allergic inflammation will reduce the risk for virus-induced exacerbations. Additional studies are needed to more fully explore the effects of asthma controllers on viral exacerbations.

SUMMARY

There is strong clinical evidence to support the interaction between allergy and viral infection with respect to the risk of developing asthma, and in the causation of asthma exacerbations. There is also growing evidence that asthma is associated with a defective immune response to both viruses and allergens. As we learn more about this interaction, the goal is to identify those patients who are at risk for viral-induced wheezing, treat the underlying problem, and prevent exacerbations of asthma. Understanding the mechanisms behind virus-induced asthma will help us design and use more effective treatment strategies.

REFERENCES

1. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332(3):133–8.
2. Olenec JP, Kim WK, Lee WM, et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J Allergy Clin Immunol 2010;125(5):1001–6.
3. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161(5):1501–7.
4. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354(9178):541–5.
5. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310(6989):1225–9.
6. Johnston NW, Johnston SL, Duncan JM, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005;115(1):132–8.
7. Johnston NW, Johnston SL, Norman GR, et al. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 2006;117(3):557–62.
8. Holt PG, Rowe J, Kusel M, et al. Toward improved prediction of risk for atopy and asthma among preschoolers: a prospective cohort study. J Allergy Clin Immunol 2010;125(3):653–9.
9. Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325(15):1067–71.
10. Peat JK, Toelle BG, Dermand J, et al. Serum IgE levels, atopy, and asthma in young adults: results from a longitudinal cohort study. Allergy 1996;51(11):804–10.
11. Illi S, von ME, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 2006;368(9537):763–70.
12. Kusel MM, de Klerk NH, Kebadze T, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 2007;119(5):1105–10.
13. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008;178(7):667–72.
14. Duff AL, Pomeranz ES, Gelber LE, et al. Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. Pediatrics 1993;92(4):535–40.
15. Rakes GP, Arruda E, Ingram JM, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 1999;159(3):785–90.
16. Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006;61(5):376–82.
17. Green RM, Custovic A, Sanderson G, et al. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002;324(7340):763.
18. Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997;336(19):1356–63.
19. Gern JE, Calhoun W, Swenson C, et al. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 1997;155(6):1872–6.
20. Mosser AG, Vrtis R, Burchell L, et al. Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues. Am J Respir Crit Care Med 2005;171(6):645–51.
21. Papadopoulos NG, Bates PJ, Bardin PG, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000;181(6):1875–84.
22. Calhoun WJ, Dick EC, Schwartz LB, et al. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994;94:2200–8.
23. Avila PC, Abisheganaden JA, Wong H, et al. Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 cold. J Allergy Clin Immunol 2000;105(5):923–32.
24. De Kluijver J, Evertse CE, Sont JK, et al. Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Care Med 2003;168:1174–80.
25. DeMore JP, Weisshaar EH, Vrtis RF, et al. Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. J Allergy Clin Immunol 2009;124(2):245–52.
26. Fleming HE, Little FF, Schnurr D, et al. Rhinovirus-16 colds in healthy and in asthmatic subjects: similar changes in upper and lower airways. Am J Respir Crit Care Med 1999;160(1):100–8.
27. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 2008;105(36):13562–7.
28. Copenhaver CC, Gern JE, Li Z, et al. Cytokine response patterns, exposure to viruses, and respiratory infections in the first year of life. Am J Respir Crit Care Med 2004;170:170–80.
29. Gern JE, Brooks GD, Meyer P, et al. Bidirectional interactions between viral respiratory illnesses and cytokine responses in the first year of life. J Allergy Clin Immunol 2006;117:72–8.
30. Rosenthal LA, Mikus LD, Tuffaha A, et al. Attenuated innate mechanisms of interferon-gamma production in rats susceptible to postviral airway dysfunction. Am J Respir Cell Mol Biol 2004;30(5):702–9.
31. Heaton T, Rowe J, Turner S, et al. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet 2005;365(9454):142–9.
32. Holt PG, Upham JW, Sly PD. Contemporaneous maturation of immunologic and respiratory functions during early childhood: implications for development of asthma prevention strategies. J Allergy Clin Immunol 2005;116(1):16–24.
33. Stern DA, Guerra S, Halonen M, et al. Low IFN-gamma production in the first year of life as a predictor of wheeze during childhood. J Allergy Clin Immunol 2007;120(4):835–41.
34. Isaacs D, Clarke JR, Tyrrell DA, et al. Deficient production of leucocyte interferon (interferon-alpha) in vitro and in vivo in children with recurrent respiratory tract infections. Lancet 1981;2(8253):950–2.
35. Parry DE, Busse WW, Sukow KA, et al. Rhinovirus-induced peripheral blood mononuclear cell responses and outcome of experimental infection in allergic subjects. J Allergy Clin Immunol 2000;105:692–8.
36. Gern JE, Vrtis R, Grindle KA, et al. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med 2000;162:2226–31.
37. Bufe A, Gehlhar K, Grage-Griebenow E, et al. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol 2002;127(1):82–8.
38. Gehlhar K, Bilitewski C, Reinitz-Rademacher K, et al. Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy 2006;36(3):331–7.
39. Papadopoulos NG, Stanciu LA, Papi A, et al. Rhinovirus-induced alterations on peripheral blood mononuclear cell phenotype and costimulatory molecule expression in normal and atopic asthmatic subjects. Clin Exp Allergy 2002;32(4):537–42.
40. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006;12(9):1023–6.
41. Wark PA, Johnston SL, Buccieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201(6):937–47.
42. Bochkov YA, Hanson KM, Keles S, et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol 2010;3:69–80.
43. Lopez-Souza N, Favoreto S, Wong H, et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol 2009;123(6):1384–90.
44. Caproni M, Antiga E, Torchia D, et al. FoxP3-expressing T regulatory cells in atopic dermatitis lesions. Allergy Asthma Proc 2007;28(5):525–8.
45. Smyth LJ, Eustace A, Kolsum U, et al. Increased airway T regulatory cells in asthmatic subjects. Chest 2010. [Epub ahead of print]. DOI:10.1378/chest.09-3079.

46. Benoit LA, Holtzman MJ. New immune pathways from chronic post-viral lung disease. Ann N Y Acad Sci 2010;1183:195–210.

47. Subrata LS, Bizzintino J, Mamessier E, et al. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol 2009;183(4):2793–800.

48. Roopen M, Yerkovich ST, Hollams E, et al. Toll-like receptor 7 function is reduced in adolescents with asthma. Eur Respir J 2010;35(1):64–71.

49. Tversky JR, Le TV, Bieneman AP, et al. Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clin Exp Allergy 2008;38(5):781–8.

50. Gill MA, Bajwa G, George TA, et al. Counterregulation between the Fc epsilon RI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 2010;184(11):5999–6006.

51. Schroeder JT, Bieneman AP, Xiao H, et al. TLR9- and Fc epsilon RI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol 2005;175(9):5724–31.

52. Kato A, Favoreto S Jr, Avila PC, et al. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol 2007;179(2):1080–7.

53. Sakamoto M, Ida S, Takishima T. Effect of influenza virus infection on allergic sensitization to aerosolized ovalbumin in mice. J Immunol 1984;132:2614–7.

54. Jakiea B, Brockman-Schneider R, Amineva S, et al. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol 2008;38(5):517–23.

55. Lopez-Souza N, Dolganov G, Dubin R, et al. Resistance of differentiated human airway epithelium to infection by rhinovirus. Am J Physiol Lung Cell Mol Physiol 2004;286(2):L373–81.

56. Holgate ST, Roberts G, Arshad HS, et al. The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis. Proc Am Thorac Soc 2009;6(8):655–9.

57. Lachowicz-Scroggins ME, Boushey HA, Finkbeiner WE, et al. Interleukin-13 induced mucous metaplasia increases susceptibility of human airway epithelium to rhinovirus infection. Am J Respir Cell Mol Biol 2010. [Epub ahead of print]. DOI:10.1165/rcmb.2009-0244OC.

58. Lemanske RF Jr, Dick EC, Swenson CA, et al. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 1989;83(1):1–10.

59. Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007;120(3):e702–12.

60. Kim CK, Choi J, Kim HB, et al. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr 2010;156(5):749–54.

61. Busse WW, Massanari M, Kianifard F, et al. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007;23(10):2379–86.